| pubmed-article:2590120 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2590120 | lifeskim:mentions | umls-concept:C0023418 | lld:lifeskim |
| pubmed-article:2590120 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:2590120 | lifeskim:mentions | umls-concept:C0037663 | lld:lifeskim |
| pubmed-article:2590120 | lifeskim:mentions | umls-concept:C0302820 | lld:lifeskim |
| pubmed-article:2590120 | lifeskim:mentions | umls-concept:C0279025 | lld:lifeskim |
| pubmed-article:2590120 | lifeskim:mentions | umls-concept:C0444956 | lld:lifeskim |
| pubmed-article:2590120 | lifeskim:mentions | umls-concept:C0332154 | lld:lifeskim |
| pubmed-article:2590120 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:2590120 | pubmed:dateCreated | 1989-12-27 | lld:pubmed |
| pubmed-article:2590120 | pubmed:abstractText | The effect on carbohydrate metabolism of a high dose growth hormone (GH) regimen (1.2 U/kg per week) was assessed on 24 children who had previously been treated for leukaemia. Sixteen patients received high dose GH and eight patients received a conventional dose of GH (0.6 U/kg per week). Oral glucose tolerance tests (OGTT) were performed at baseline and after 3 months of treatment with GH. For the entire group between 0 and 3 months, there was a significant increase in mean (and standard deviation) fasting plasma glucose (0.3 +/- 0.6 mmol/L), fasting insulin level (11 +/- 26 mU/L), and 2 h insulin level (20 +/- 40 mU/L). One patient, who received a conventional dose of GH, developed substantial carbohydrate intolerance. For the entire group, there was no change in response to a carbohydrate load at 3 months as measured by the area under the plasma glucose or insulin curve. There was no significant difference between conventional and high dose groups at 3 months as assessed by these parameters. This study demonstrates that a higher dose of GH may be used in these children in an attempt to improve their final height, without increased risk of carbohydrate intolerance in the short term. | lld:pubmed |
| pubmed-article:2590120 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2590120 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2590120 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2590120 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2590120 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2590120 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2590120 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:2590120 | pubmed:issn | 0004-993X | lld:pubmed |
| pubmed-article:2590120 | pubmed:author | pubmed-author:SilinkMM | lld:pubmed |
| pubmed-article:2590120 | pubmed:author | pubmed-author:HowardN JNJ | lld:pubmed |
| pubmed-article:2590120 | pubmed:author | pubmed-author:GreenacrePP | lld:pubmed |
| pubmed-article:2590120 | pubmed:author | pubmed-author:StevensM MMM | lld:pubmed |
| pubmed-article:2590120 | pubmed:author | pubmed-author:CrawfordB ABA | lld:pubmed |
| pubmed-article:2590120 | pubmed:author | pubmed-author:CowellC TCT | lld:pubmed |
| pubmed-article:2590120 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2590120 | pubmed:volume | 25 | lld:pubmed |
| pubmed-article:2590120 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2590120 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2590120 | pubmed:pagination | 236-40 | lld:pubmed |
| pubmed-article:2590120 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2590120 | pubmed:meshHeading | pubmed-meshheading:2590120-... | lld:pubmed |
| pubmed-article:2590120 | pubmed:meshHeading | pubmed-meshheading:2590120-... | lld:pubmed |
| pubmed-article:2590120 | pubmed:meshHeading | pubmed-meshheading:2590120-... | lld:pubmed |
| pubmed-article:2590120 | pubmed:meshHeading | pubmed-meshheading:2590120-... | lld:pubmed |
| pubmed-article:2590120 | pubmed:meshHeading | pubmed-meshheading:2590120-... | lld:pubmed |
| pubmed-article:2590120 | pubmed:meshHeading | pubmed-meshheading:2590120-... | lld:pubmed |
| pubmed-article:2590120 | pubmed:meshHeading | pubmed-meshheading:2590120-... | lld:pubmed |
| pubmed-article:2590120 | pubmed:meshHeading | pubmed-meshheading:2590120-... | lld:pubmed |
| pubmed-article:2590120 | pubmed:meshHeading | pubmed-meshheading:2590120-... | lld:pubmed |
| pubmed-article:2590120 | pubmed:meshHeading | pubmed-meshheading:2590120-... | lld:pubmed |
| pubmed-article:2590120 | pubmed:meshHeading | pubmed-meshheading:2590120-... | lld:pubmed |
| pubmed-article:2590120 | pubmed:meshHeading | pubmed-meshheading:2590120-... | lld:pubmed |
| pubmed-article:2590120 | pubmed:meshHeading | pubmed-meshheading:2590120-... | lld:pubmed |
| pubmed-article:2590120 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2590120 | pubmed:articleTitle | Carbohydrate metabolism on high dose growth hormone therapy in children treated for leukaemia. | lld:pubmed |
| pubmed-article:2590120 | pubmed:affiliation | Institute of Endocrinology, Children's Hospital, Camperdown, New South Wales, Australia. | lld:pubmed |
| pubmed-article:2590120 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2590120 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
